The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
The US Court of Appeals for the Seventh Circuit has upheld a preliminary injunction from an Illinois court that blocked medical device maker Aegis Spine from selling its spinal implant.
Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
The US Federal Trade Commission has dropped its remaining claim in a lawsuit against AbbVie and Besins Healthcare, after the US Supreme Court declined to rule that consumers had a right to be compensated by the companies.
The US Senate Judiciary Committee has unanimously voted to pass four bills that aim to crack down on anti-competitive practices in the pharmaceutical industry.
In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
A New York federal court has denied biotechnology company Amyris’ bid for arbitration in an $881 million trade secrets and patent infringement dispute with cannabis firm Lavvan.